Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -32.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.50% |
| Dec 31, 2025 | 146.45% |
| Sep 30, 2025 | 4,089.72% |
| Jun 30, 2025 | 2,418.83% |
| Mar 31, 2025 | 3,020.72% |
| Dec 31, 2024 | 516.36% |
| Sep 30, 2024 | -93.85% |
| Jun 30, 2024 | 62.01% |
| Mar 31, 2024 | -40.52% |
| Dec 31, 2023 | 27.50% |
| Sep 30, 2023 | 157.03% |
| Jun 30, 2023 | -94.09% |
| Mar 31, 2023 | -89.19% |
| Dec 31, 2022 | -82.36% |
| Sep 30, 2022 | -87.11% |
| Jun 30, 2022 | -31.22% |
| Mar 31, 2022 | 280.98% |
| Dec 31, 2021 | 192.04% |
| Sep 30, 2021 | 277,274.75% |
| Jun 30, 2021 | 601,525.64% |